Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Terahertz Dielectric Characterization and Hybrid Debye-Lorentz Modeling of Silicone Rubber Composites for Composite Insulators.

Polymers·2026
Same author

IgA is necessary and sufficient to prevent norovirus infection in mice.

Science translational medicine·2026
Same author

Corrections to "Reprogramming Tumor-Associated Macrophages To Reverse EGFR<sup>T790M</sup> Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat".

Nano letters·2026
Same author

ENPP1 blockade with a humanized monoclonal antibody enhances renal repair after acute kidney injury.

Cell stem cell·2026
Same author

Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT.

Nature biotechnology·2026
Same author

Spatially resolved m<sup>6</sup>A profiling using m<sup>6</sup>A-ARTR-DBiT.

Nature methods·2026

相关实验视频

Updated: Jan 13, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

针对实体瘤的CAR-T药物联合体.

Shan Xin, Yanzhi Feng, Feifei Zhang

    bioRxiv : the preprint server for biology
    |January 9, 2026
    PubMed
    概括
    此摘要是机器生成的。

    卡尔-T-药物联合体 (CAR-T-D-Cs) 提供了一种新的免疫化疗方法. 这种双重功能疗法通过将细胞毒性药物直接输送到瘤部位来增强CAR-T细胞透和在固体瘤中的疗效.

    更多相关视频

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    22.0K
    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.7K

    相关实验视频

    Last Updated: Jan 13, 2026

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
    09:56

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

    Published on: February 21, 2025

    1.3K
    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    22.0K
    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.7K

    科学领域:

    • 免疫治疗是一种免疫疗法.
    • 在瘤学瘤学.
    • 药物运输 药物运输 药物运输

    背景情况:

    • 化学抗原受体 (CAR) -T细胞疗法在血液癌症中取得了成功,但由于透不良和免疫抑制性瘤微环境 (TME),它与固体瘤作斗争.
    • 传统的CAR-T细胞组合疗法和化疗通常会导致显著的全身毒性.

    研究的目的:

    • 引入CAR-T-药物联合体 (CAR-T-D-C) 作为固体瘤的新型双功能治疗策略.
    • 研究CAR-T-D-C在克服TME挑战和增强CAR-T细胞介导的抗瘤活性方面的疗效.

    主要方法:

    • 使用点击化学开发CAR-T-D-C,用于精确将细胞毒剂与抗原特异性CAR-T细胞结合.
    • 在各种固体瘤模型中评估CAR-T-D-C抗瘤活性,包括人类异种移植和异种模型.
    • 空间转录组分析以评估TME内的CAR-T细胞透,激活和免疫反应.

    主要成果:

    • 在各种固体瘤模型中,CAR-T-D-C表现出强大的抗瘤活性.
    • 空间转录组学证实,在TME内改善了CAR-T细胞透和功能激活.
    • 与传统的CAR-T疗法相比,CAR-T-D-C疗法增强了免疫细胞透,效应器功能,抗原扩散,全身免疫反应和整体抗瘤免疫力.

    结论:

    • CAR-T-D-C代表了一种针对固体瘤的多功能2合1免疫化疗方法.
    • 这一策略有效地将TME转化为盟友,使细胞毒性有效载荷的局部传递成为可能,并提高了CAR-T治疗的有效性.
    • CAR-T-D-C将小分子药物的功效与CAR-T细胞的特异性结合在一起,为癌症治疗提供了一个有前途的新途径.